Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
5‑phenyl‑1H‑indazol‑3‑amine is a synthetic small molecule belonging to the indazole class of organic compounds. It has the molecular formula C13H11N3 and a molecular weight of approximately 209.25 g/mol[1][8][9][10]. This compound is primarily studied as an experimental agent and is not approved for clinical use in any country[1]. Its main mechanism of action is inhibition of tyrosine-protein kinase JAK2, with reported IC50 values around 1600 nM[1]. As a JAK2 inhibitor, it may have potential applications in modulating signaling pathways involved in inflammation and cancer, but there are no known clinical trials or approved indications for this compound as of now[1][2].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on 5-phenyl-1H-indazol-3-amine.